New: Instantly spot drawdowns, dips, insider moves, and breakout themes across Maps and Screener.

Elutia Inc.

Contributing Author

Recent Articles by Elutia Inc.

Jan-12	Elutia Reports Preliminary Fourth Quarter 2025 Results, Strengthened Financial Position, and Upcoming NXT-41x Milestones ELUT GlobeNewswire
Jan-09	Elutia to Present at Global BioInnovation Forum on NXT-41x Biomatrix Program for Plastic and Reconstructive Surgery ELUT GlobeNewswire
Nov-06	Elutia Reports Third Quarter 2025 Financial Results; Closes $88 Million Sale of BioEnvelope Business to Boston Scientific Corporation; Funds NXT-41x Development ELUT GlobeNewswire
Oct-23	Elutia to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025 ELUT GlobeNewswire
Oct-14	Elutia to Present at the LD Micro Main Event XIX Conference on Tuesday, October 21 ELUT GlobeNewswire
Oct-10	Elutia Appoints Accomplished MedTech Veteran Guido J. Neels to Board of Directors ELUT GlobeNewswire
Oct-01	Elutia Announces Closing of BioEnvelope Business Sale to Boston Scientific Corporation for $88 Million ELUT GlobeNewswire
Sep-16	Elutia Announces Newly Published Clinical Data Demonstrating that Biologic Envelopes Support CIED Stabilization and Ease of Reoperation ELUT GlobeNewswire
Sep-09	Elutia Announces Sale of BioEnvelope Business to Boston Scientific Corporation for $88 Million ELUT GlobeNewswire
Sep-04	Elutia Selected to Exhibit EluPro Antibiotic Eluting BioEnvelope at Vizient Innovative Technology Exchange ELUT GlobeNewswire
Aug-27	Elutia to Participate in Upcoming Investor Conferences ELUT GlobeNewswire
Aug-14	Elutia Delivers Robust Growth on the Strength of EluPro Market Adoption ELUT GlobeNewswire
Jul-31	Elutia to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025 ELUT GlobeNewswire
Jul-31	Dr. Michelle LeRoux Williams Earns Washington Business Journal's Medical Device Innovator Award ELUT GlobeNewswire
Jul-01	New Evidence Supports the Value of Elutia's Antibiotic-Eluting Platform for Implantable Devices ELUT GlobeNewswire
May-28	Elutia Strengthens Drug-Eluting Biomatrix Platform with Peer-Reviewed Publication of Novel EluPro Testing Method ELUT GlobeNewswire
May-08	Elutia Announces Strong First Quarter 2025 Financial Results Driven by 84% Sequential Growth in EluPro Sales ELUT GlobeNewswire
May-01	Elutia Transitions to Direct Distribution of Its Cardiovascular Product Portfolio ELUT GlobeNewswire
May-01	Elutia to Report First Quarter 2025 Financial Results on Thursday, May 8, 2025 ELUT GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.